Product Description: Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Türeci Ӧ, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018 Nov 10;8(1):e1523096. /[2]Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Front Immunol. 2022 Jun 28;13:885424./[3]Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080.
CAS Number: 1496553-00-4
Molecular Weight: N/A
Compound Purity: 96.98
Research Area: Cancer
Solubility: H2O
Target: Others
English
Deutsch
